Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib with Fulvestrant and Palbociclib in HR+/HER2- Metastatic Breast Cancer
NCT03377101Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Aug 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of copanlisib in Hormone-Receptor-Positive Breast Cancer, sponsored by National Cancer Institute. Planned start Aug 2018; status: withdrawn.
02
Drugs
copanlisib
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT03377101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03377101.